Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Stocks
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
tag
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
IPO
2026 World Cup
Rewards

Immvira Bioscience Files Listing Application to Hong Kong Stock Exchange on July 16, Third Submission

GateNews
Stocks
C1.23%

According to Hong Kong Exchanges and Clearing disclosure on July 16, Immvira Bioscience Inc. submitted its listing application to the Main Board, with Citigroup and China International Capital Corporation as joint sponsors. The biotech company develops oncolytic immunotherapies and engineered exosome therapies for clinical unmet needs.

The company's pipeline includes two oncolytic immunotherapy products for solid tumors and five engineered exosome products with clinical potential or direct commercialization prospects, according to the prospectus.

View Source
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

2h ago
Baidu Applies for Dual Primary Listing on Hong Kong and Nasdaq, Expected to Complete This Year
5h ago
Syngenta Group Postpones Planned $5B Hong Kong IPO to 2027, Cites Agricultural Market Challenges
23h ago
Yongyou Network Files IPO Application with Hong Kong Exchange on July 15
07-15 11:06
China Optoelectronics Leader Zhongji Xuangchuang Plans Hong Kong IPO Raising $7B, Hearing Earliest This Week
07-15 07:36
China Health Industries Submits Hong Kong IPO Prospectus on June 30, Leads Pediatric CSO Market With 17% Share
In-Depth Analysis

LigaChem Biosciences Revises 500 Billion Won Fundraising Terms with Lower Conversion Price

Crypto Frontier1h ago

EcoPro BM CEO Defends 1.2 Trillion Won Capital Increase for Nickel Smelter

Lucas Bennett2h ago

Bloomberg: Anthropic stock could be listed as early as October; three major investment banks are arranging meetings between investors and executives

Market Whisper7h ago
Comment
0/400
No comments